Human immunodeficiency virus type 1 (HIV-1) Vif requires core binding factor β (CBF-β) to degrade the host APOBEC3 restriction factors. Although a minimum domain and certain amino acids of HIV-1 Vif, including hydrophobic residues at the N-terminal, have been identified as critical sites for binding with CBF-β, other regions that potentially mediate this interaction need to be further investigated. Here, we mapped two new regions of HIV-1 Vif that are required for interaction with CBF-β by generating a series of single-site or multiple-site Vif mutants and testing their effect on the suppression of APOBEC3G (A3G) and APOBEC3F (A3F). A number of the mutants, including G84A/SIEW86-89AAAA (84/86–89), E88A/W89A (88/89), G84A, W89A, L106S and I107S in the 84GxSIEW89 and L102ADQLI107 regions, affected Vif function by disrupting CBF-β binding. These Vif mutants also had altered interactions with CUL5, since CBF-β is known to facilitate the binding of Vif to CUL5. We further showed that this effect was not due to misfolding or conformational changes in Vif, as the mutants still maintained their interactions with other factors such as ElonginB, A3G and A3F. Notably, G84D and D104A had stronger effects on the Vif-CUL5 interaction than on the Vif-CBF-β interaction, indicating that they mainly influenced the CUL5 interaction and implying that the interaction of Vif with CUL5 contributes to the binding of Vif to CBF-β. These new binding interfaces with CBF-β in HIV-1 Vif provide novel targets for the development of HIV-1 inhibitors.
References
[1]
Zhang W, Du J, Evans SL, Yu Y, Yu XF (2012) T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481: 376–379. doi: 10.1038/nature10718
[2]
Matsui Y, Shindo K, Nagata K, Io K, Tada K, et al. (2014) Defining HIV-1 Vif residues that interact with CBFbeta by site-directed mutagenesis. Virology 449: 82–87.
[3]
Zhou X, Han X, Zhao K, Du J, Evans SL, et al. (2014) Dispersed and Conserved Hydrophobic Residues of HIV-1 Vif Are Essential for CBFbeta Recruitment and A3G Suppression. J Virol 88: 2555–2563.
[4]
Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646–650. doi: 10.1038/nature00939
[5]
Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, et al. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79: 285–296.
[6]
Zhen A, Du J, Zhou X, Xiong Y, Yu XF (2012) Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PLoS One 7: e38771. doi: 10.1371/journal.pone.0038771
[7]
Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, et al. (2012) Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481: 371–375. doi: 10.1038/nature10693
[8]
Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS (2012) Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. J Virol 86: 2874–2877. doi: 10.1128/jvi.06950-11
[9]
de Bruijn MF, Speck NA (2004) Core-binding factors in hematopoiesis and immune function. Oncogene 23: 4238–4248. doi: 10.1038/sj.onc.1207763
[10]
Wissing S, Montano M, Garcia-Perez JL, Moran JV, Greene WC (2011) Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J Biol Chem 286: 36427–36437. doi: 10.1074/jbc.m111.251058
[11]
Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, et al. (2013) CBFbeta stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol Cell 49: 632–644. doi: 10.1016/j.molcel.2012.12.012
[12]
Zhou X, Evans SL, Han X, Liu Y, Yu XF (2012) Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFbeta and CRL5 E3 ubiquitin ligase components. PLoS One 7: e33495. doi: 10.1371/journal.pone.0033495
[13]
Du J, Zhao K, Rui Y, Li P, Zhou X, et al. (2013) Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J Virol 87: 1906–1911. doi: 10.1128/jvi.02199-12
[14]
Guo Y, Dong L, Qiu X, Wang Y, Zhang B, et al. (2014) Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505: 229–233. doi: 10.1038/nature12884
[15]
Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev 18: 2861–2866. doi: 10.1101/gad.1249904
[16]
Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF (2004) Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev 18: 2867–2872. doi: 10.1101/gad.1250204
[17]
Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, et al. (2005) Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A 102: 11444–11449. doi: 10.1073/pnas.0502440102
[18]
Paul I, Cui J, Maynard EL (2006) Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc Natl Acad Sci U S A 103: 18475–18480. doi: 10.1073/pnas.0604150103
[19]
He Z, Zhang W, Chen G, Xu R, Yu XF (2008) Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol 381: 1000–1011. doi: 10.1016/j.jmb.2008.06.061
[20]
Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF (2008) Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One 3: e3963. doi: 10.1371/journal.pone.0003963
[21]
Tian C, Yu X, Zhang W, Wang T, Xu R, et al. (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol 80: 3112–3115. doi: 10.1128/jvi.80.6.3112-3115.2006
[22]
Dang Y, Davis RW, York IA, Zheng YH (2010) Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J Virol 84: 5741–5750. doi: 10.1128/jvi.00079-10
[23]
Wang X, Zhang H, Lv M, Zuo T, Wu H, et al. (2013) Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-beta binding to Vif. Retrovirology 10: 94. doi: 10.1186/1742-4690-10-94
[24]
Fribourgh JL, Wolfe LS, Nguyen HC, Dewitt DC, Zhang W, et al. (2014) CBFbeta plays a critical role facilitating the assembly of the Vif-Cul5 E3 ubiquitin ligase. J Virol.
[25]
Russell RA, Pathak VK (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81: 8201–8210. doi: 10.1128/jvi.00395-07
[26]
Chen G, He Z, Wang T, Xu R, Yu XF (2009) A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol 83: 8674–8682. doi: 10.1128/jvi.00653-09
[27]
Dang Y, Wang X, Zhou T, York IA, Zheng YH (2009) Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J Virol 83: 8544–8552.
[28]
Pery E, Rajendran KS, Brazier AJ, Gabuzda D (2009) Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol 83: 2374–2381.
[29]
Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, et al. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 78: 6073–6076. doi: 10.1128/jvi.78.11.6073-6076.2004
[30]
Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056–1060. doi: 10.1126/science.1089591
[31]
Chackerian B, Long EM, Luciw PA, Overbaugh J (1997) Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol 71: 3932–3939.
